Pavmed Inc (PAVM)

May 14, 2025, 8:01 AM EDT - 22 hours ago

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

LUCD

May 1, 2025, 8:31 AM EDT - 13 days ago

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

LUCD

Apr 30, 2025, 8:31 AM EDT - 14 days ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

LUCD

Apr 24, 2025, 8:01 AM EDT - 20 days ago

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

LUCD

Apr 11, 2025, 9:23 AM EDT - 4 weeks ago

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

LUCD

Apr 9, 2025, 7:24 PM EDT - 5 weeks ago

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

LUCD

Apr 9, 2025, 4:01 PM EDT - 5 weeks ago

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

LUCD

Apr 3, 2025, 9:00 AM EDT - 5 weeks ago

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

LUCD

Mar 27, 2025, 8:01 AM EDT - 6 weeks ago

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

LUCD

Mar 25, 2025, 11:08 AM EDT - 7 weeks ago

PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 8:01 AM EDT - 7 weeks ago

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 24, 2025, 8:01 AM EDT - 7 weeks ago

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

LUCD

Mar 20, 2025, 8:31 AM EDT - 7 weeks ago

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

LUCD

Mar 18, 2025, 8:31 AM EDT - 2 months ago

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

LUCD

Mar 13, 2025, 7:36 AM EDT - 2 months ago

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

LUCD

Mar 10, 2025, 9:01 AM EDT - 2 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

LUCD

Mar 5, 2025, 4:45 PM EST - 2 months ago

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

LUCD

Mar 4, 2025, 8:25 AM EST - 2 months ago

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

LUCD

Feb 27, 2025, 8:31 AM EST - 2 months ago

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

LUCD

Feb 25, 2025, 8:31 AM EST - 2 months ago

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

LUCD

Feb 24, 2025, 8:31 AM EST - 2 months ago

PAVmed and Subsidiary Veris Health Complete Private Placement Financing

Feb 20, 2025, 8:31 AM EST - 2 months ago

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

LUCD

Feb 18, 2025, 8:30 AM EST - 3 months ago

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

LUCD

Feb 6, 2025, 8:57 AM EST - 3 months ago

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LUCD

Jan 13, 2025, 7:56 AM EST - 4 months ago

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

LUCD

Dec 23, 2024, 8:01 AM EST - 5 months ago

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

LUCD

Dec 19, 2024, 8:01 AM EST - 5 months ago

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

LUCD

Dec 11, 2024, 8:01 AM EST - 5 months ago

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

LUCD

Dec 3, 2024, 8:01 AM EST - 5 months ago

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

LUCD

Nov 20, 2024, 7:56 AM EST - 6 months ago

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

LUCD

Nov 18, 2024, 8:15 AM EST - 6 months ago

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

LUCD

Nov 14, 2024, 3:49 PM EST - 6 months ago

PAVmed Inc. (PAVM) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:01 AM EST - 6 months ago

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

Nov 13, 2024, 8:01 AM EST - 6 months ago

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results

LUCD

Nov 7, 2024, 8:01 AM EST - 6 months ago

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

LUCD

Nov 5, 2024, 8:01 AM EST - 6 months ago

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

LUCD

Oct 31, 2024, 8:31 AM EDT - 6 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024

Oct 30, 2024, 8:31 AM EDT - 7 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

LUCD

Oct 15, 2024, 7:51 AM EDT - 7 months ago

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

LUCD

Oct 10, 2024, 7:51 AM EDT - 7 months ago

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care

Oct 9, 2024, 8:01 AM EDT - 7 months ago

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

LUCD

Oct 8, 2024, 7:49 AM EDT - 7 months ago

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

LUCD

Sep 24, 2024, 8:01 AM EDT - 8 months ago

American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

LUCD

Sep 16, 2024, 4:30 PM EDT - 8 months ago

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

LUCD

Sep 10, 2024, 7:56 AM EDT - 8 months ago

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress

LUCD

Sep 3, 2024, 7:51 AM EDT - 9 months ago

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

LUCD

Aug 20, 2024, 8:16 AM EDT - 9 months ago

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

LUCD

Aug 13, 2024, 6:59 PM EDT - 9 months ago

PAVmed Inc. (PAVM) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 8:16 AM EDT - 9 months ago

The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer

LUCD

Aug 13, 2024, 8:01 AM EDT - 9 months ago

PAVmed Provides Business Update and Second Quarter 2024 Financial Results

LUCD